 
 2
摘要 
 表皮生長因子接受(EGFR)器常在人類的癌細胞過量表現，當其與表皮生長因子(EGF)結合後可引發
眾多訊息傳導，導致細胞增生並與血管新生、細胞轉移等生理功能，與癌症難以治療有著相當大的關
連性。透過抑制EGFR-EGF 交互作用的抗癌藥物，於治療上有相當程度的效果，但亦對正常細胞產生影
響，導致嚴重的副作用。進一步地去瞭解EGFR-EGF 之交互作用，將有助於抗癌藥物之發展。 
 本研究之目的在建立三個主要 EGFR 與EGF 交互作用的模型，包括接受器-配基結合、接受器雙體
化、接受器磷酸化，並藉此模型評估小分子調控此交互作用的可行性。首先，選定各種型態之EGFR，
分別固定於微流體晶片上，透過表面電漿共振偵測器，以動力學參數呈現EGFR-EGF 之交互作用。實驗
中，探討EGFR 的固定量、EGF 的濃度以及流速對偵測EGFR-EGF 之交互作用動力學常數的影響，尋找
能準確測量EGFR-EGF 動力學的條件，獲得代表EGFR-EGF 之動力學參數。 
 另一方面，透過此模型分析六十種中藥中所含小分子對 EGFR-EGF 交互作用的影響，評估是否有
小分子具能調節EGFR-EGF 之能力？再利用已建立的快速分析技術，分析這些混合物中真正參與調節作
用的小分子。 
Abstract 
 Over-expression of EGFR (Epidermal Growth Factor Receptor) has always been observed in human 
cancer cells. As soon as EGF (Epidermal Growth Factor) binds EGFR, it causes EGFR tyrosine kinase 
domain activation, and downstream signal transductions including cell proliferation, angiogenesis and 
metastasis. Cancer which hard to cure is known as associated with all of these signal transductions. Some 
reports showed that EGFR inhibitors induce side effects due to its lower selectivity to cancer cell. To study 
EGF-EGFR interactions can help to develop anti-cancer drug discovery. 
 In this study, the goal is to set up a model to investigate 3 of EGFR-EGF interactions, included 
receptor-ligand binding, dimerization and phosphorylation, and by using it to estimate the possibility of 
modulation to EGFR–EGF interaction. Firstly, EGFR are immobilized on a micro-fluidic chip with a SPR 
(Surface Plasmon Resonance) detector. Kinetic parameters of EGFR-EGF interaction are measured at 
different conditions. The effect of immobilized EGFR density, EGF concentration and flow rate on kinetic 
study is evaluated. It gives an optimal condition for measuring EGFR-EGF kinetic parameters accurately and 
following screen small molecular modulators. 
 Besides, by using the model, 60 of TCMs (Traditional Chinese Medicines) are used to pre-treat EGFR. 
The effect of TCMs on kinetic parameters and selectivity of EGFR modulation are measured as soon. Finally, 
we can use a established method to identify the active component in TCM. 
 4
肆、 研究方法、 
蛋白質的選擇 
    在代表正常細胞的 EGFR 挑選上，我們使用為 Sigma 公司所生產的 EGFR，它具有完整的膜外區
域及膜內區域，是一個 low-affinity EGFR monomer ；在代表癌細胞的 EGFR 的選擇上，使用為 R&D
公司所生產 EGFR ，它是一個 high-affinity EGFR dimer 的結構，可代表癌細胞上 EGFR 的膜外片段的
結構，但此蛋白並不具有膜內區域，所以需連結 IgG 來維持其膜外區域的結構，此兩種不同型態 EGFR
的膜外結構，剛好可以分別代表 EGFR 在癌細胞與正常細胞上不一樣的膜外區域的結構。(對於分別代
表癌細胞與正常細胞 EGFR 的分析，實驗步驟皆同，故在以下實驗步驟之描述，皆以 EGFR 代稱之，
不做額外區分) 
蛋白質晶片製備 
EGFR 固定  在 EGFR 固定上，選用晶片表面為羧基的 CM5 晶片，運用與其 EGFR 膜內片段的胺基固
定，減低在固定時 EGFR 膜外區域遭受破壞的風險。     
    在 EGFR 緩衝溶液選擇上沿用 acetate solution，由於 EGFR 固定於晶片是利用 CM5 晶片的羧基表
面進行反應，晶片的羧基表面在微流體管路 running buffer 中是一個略帶負電的環境，所以 EGFR 若能
帶些微正電，可以提高固定效率，故使用大於晶片的羧基表面 pH 3.5，且低於 EGFR 的等電位點的緩
衝溶液，可使 EGFR 在緩衝溶液中略帶正電，實驗中選取 pH 4.5、 pH 5.0 、pH 5.5 的三種不同 pH 值
緩衝溶液各 30 µl，在流速 10 µl/min 的條件下注入未固定蛋白質的晶片表面，觀察其吸附作用情況而判
斷之。 
    完成上述對 acetate solution 之 pH 値的選擇後，配製 100 µl 濃度 10 µg/ml 的 EGFR，以 HBS-EP buffer
為 running buffer，進行 EGFR 的固定三步驟，第一步為注入 EDC/NHS solution 活化晶片表面，第二步
為注入 EGFR 固定，第三步以 EA solution 將未反應之官能基去活化，即完成 EGFR 固定，並依據實驗
需求的不同，可透過改變注入 EDC/NHS 的多寡影響晶片表面的活化程度以及注入 EGFR 的多寡來改
變其固定量。 
    在完成 EGFR 固定步驟後，需對 EGFR 進行測試，確定 EGFR 在固定後依舊維持其活性結構，並
無在固定過程中遭受損壞。 
EGFR 固定後位向測試  以 PBS 配製 10 µg/ml 的 anti-EGFR (epitope: EGF binding site) 100 µl，在
BIAcore 系統中，以 PBS 為 running buffer 在流速 10 µl/min 的環境中，使用 Injection 模式注入 30 µl 
anti-EGFR，並等待與其注入時間相等的時間後，以觀察其解離情形，最後使用 Quick Injection 模式注
入 5 µl 濃度為 50 mM NaOH solution 以 100 µl/min 流速下進行晶片清洗(regeneration)，可得 anti-EGFR
對 EGFR 交互作用之訊號圖，透過其 BIAcore 附屬程式計算在晶片上固定後的 EGFR 與 anti-EGFR，是
否還維持著應有的親和力。 
EGFR 固定後活性測試  以 PBS 配製 10 µg/ml 的 EGF 100 µl，在 BIAcore 系統中，以 PBS 為 running 
buffer 在流速 10 µl/min 的環境中，使用 Injection 模式注入 30 µl 的 EGF，並等待與其注入時間相等的
時間後，才使用 Quick Injection 模式注入 5 µl 濃度為 50 nM NaOH solution 以 100 µl/min 流速下進行晶
片清洗，可得 EGF 對 EGFR 的 SPR 偵測圖，判斷在固定後的 EGFR，對 EGF 是否還維持著應有的結
合能力。 
小分子的樣品製備 
    因為本研究中利用對中草藥樣品的萃取來提供實驗中所需大量的小分子來源，目前中草藥中並無
特定樣品針對癌症有治療之效果，所以並無特定的挑選方法，故從本實驗室中已經過編號分類的一百
二十種順天堂科學中藥，隨機取樣挑選六十種進行分析，所挑選之六十種中草藥樣品如下表 3.1 所示: 
 
 
 6
生，觀察其解離情形，進行 EGF-EGFR 的結合動力學，利用 BIAcore 計算程式分析，不同流速下其動
力學常數變化與質量轉移常數之變化，進而選擇一合適流速環境。 
小分子處理後與 EGFR-EGF 動力學與親和力差異 
    在固定 EGFR 後，在流速 10 µl/min 的以 PBS 為 running buffer 的條件下，先注入 30 µl 濃度為 2.5 
µg/ml 的 EGF，等待約 180 秒後，注射 5 µl 濃度為 50 nM NaOH solution，以 100 µl/min 流速下進行晶
片清洗(regeneration)，將留於 EGFR 上的 EGF洗掉，此時一樣在流速 10 µl/min 的以 PBS為 running buffer
的條件下，注入配置好濃度的中草藥萃取物溶液 30 µl，並等待其解離過程趨於平衡後，在一樣晶片條
件下再次注入 30 µl 濃度為 2.5 µg/ml 的 EGF，等待約 180 秒後，一樣進行晶片再生動作，重覆此步驟
完成六十個中草藥萃取物與 EGFR-EGF 結合之關係圖。 
小分子之活性成份分析 
活性成份之標定與純化 
從晶片回收活性成份  利用 BIAcore 3000 的回收程式，將欲回收之中草藥萃取物樣品，以前述實驗方
法配製成溶液，在固定有 EGFR 晶片上，以流速 10 µl/min 的以 PBS 為 running buffer 的條件下，注入
中藥萃取物溶液 15 µl，並等待其解離過程趨於平衡後，注射 7 µl 濃度為 50 nM NaOH solution，停滯
時間為 10 秒，進行晶片回收，重覆此步驟 40 次，將所得回收溶液清洗部分，利用機器手臂收於 200 µl
微量離心管中，於 60℃條件下經由離心機轉速 10000 r.p.m.下離心，可去除溶液，得到微量的中藥萃取
物樣品與 EGFR 特異性結合成分。 
活性成分之 HPLC 比對與鑑定  將萃取後保存於微量離心管中之中草藥樣品，溶於 1 ml 二次水，使
用 0.45 µm 過濾膜過濾，在沖提條件為流速 1 ml/min，以 100%水為初始沖提液，沖提 5 分鐘後，開始
梯度沖提在 100 分鐘內沖提液線性上升至為 100%甲醇，在以 100 %為沖提液沖提 5 分鐘後結束，可得
此中草藥樣品之 HPLC 圖譜，在以此圖為標準，配合實驗需求，進行沖提條件的改變。 
    051 樣品的最佳沖提條件為在 254 nm 的波長下，以 60 %水與 40 %ACN(Acetonitrile) 沖提 35 分鐘
後，開始梯度沖提增加 ACN 的比例於 40 分鐘時，改變為 25 %水與 75 % ACN，以此條件持續沖提至
65 分鐘，再此梯度沖提於 70 分鐘時，改變為 10 % 水與 90 % ACN 沖提，以此條件持續沖提至 90 分
鐘結束。051 樣品在上述沖提條件下，分別注入 20 µl 萃取物樣品以及回收後之樣品進行活性成分的比
對。 
活性成分的純化  051 樣品之 peak B 的最佳沖提條件為在 254 nm 的波長下，以 60 %水與 40 
%ACN(Acetonitrile) 沖提 35 分鐘後，開始梯度沖提增加 ACN 的比例於 40 分鐘時，改變為 25 %水與
75 %ACN，以此條件持續沖提至 65 分鐘，再此梯度沖提於 70 分鐘時，改變為 10 %水與 90 %ACN 沖
提，以此條件持續沖提至 90 分鐘結束。 
單一活性成份對 EGFR 之影響 
同 3.2.2 實驗步驟，將注入中藥萃取物改為經 3.3.1 實驗經 HPLC 分析所得之 051 樣品之 peak B 成份，
可得 peak B 對 high-affinity EGFR-EGF 之作用圖。 
 
伍、  結果與討論（含結論與建議） 
 Determine by rate constant and equilibrium constant 
A. interaction at ligand binding、dimerization、phosphorylation by using SPR 
B. types of EGFR 
C. conc of ligand 
D. amount of immobilized EGFR 
E. flow rate 
F. 固定方法：直接與間接等 
為了探討中草藥樣品中對 EGFR 產生的特異性結合的小分子，其能否影響 EGFR-EGF 結合，其分
 8
  進一步觀察 041 及 051 對 EGF-EGFR binding 的影響，可以發現 041 可以有效增加 EGF 結合至
EGFR 的速度(ka)，並降低 EGF 由 EGFR 上解離的速度(kd)，來達到使 EGF 對 EGFR 親和力上升的效
果。反之，051 則有效增加 EGF 至 EGFR 上解離的速度(kd)，並降低結合至 EGFR 的速度(ka)，來達
到使 EGF 對 EGFR 親和力下降的效果(Fig 5 and table 1)。 
  欲評估此三種樣品於 EGF-EGFR 所誘導的細胞分裂或是抗凋亡的影響，我們選用 A549 肺癌細胞
株進行細胞存活試驗(MTT assay)。從結果觀察到在低濃度之下(10ug/ml)，三種樣品影響差異並不顯
著，但於較高濃度(100ug/ml)處理下，051 展現了很好的細胞生長抑制效果，040 則反而讓細胞增生速
度增加，而 035 則影響不大。此結果和上述之親和力影響成正相關。 
從親和力及細胞實驗的相關性可以推測，051 確實是 EGF-EGFR binding 上有效的抑制劑，051 可以透
過與 EGFR 結合後，進而降低 EGF 結合至 EGFR 的親和力及結合量，來抑制 EGFR 所操控的細胞增
生及抑制凋亡作用，最後使肺癌細胞數目明顯的減少。而 040 則是 EGF-EGFR binding 上有效的促進，
040 可以透過與 EGFR 結合後，進而增加 EGF 結合至 EGFR 的親和力及結合量，來促進 EGFR 所操
控的細胞增生及抑制凋亡作用，最後使肺癌細胞數目明顯的增加。我們利用 EGF-EGFR binding 上親
和力的調控，來影響最終在細胞上顯現的活性。這樣的結果可以應用於許多以蛋白質交互作用異常為
病因的相關疾病，對於未來藥物研發有很大的助益。 
 
發表 
1. Kuo WT, Ho YJ, Kuo SM, Lin FH, Tsai FJ, Chen YS*, Dong GC*, Yao CH* 2011, “Induction of the 
Mitochondria Apoptosis Pathway by Phytohemagglutinin Erythroagglutinating in Human Lung Cancer 
Cells”, Ann Surg Oncol, 18, 3, 848-856. (SCI=4.130, Ranking 6/167<25% ) 
2. Shih-Ching Wu, Wei-Hong Chang, Guo-Chung Dong*, Kuo-Yu Chen, Yueh-Sheng Chen*, Chun-Hsu 
Yao* 2011, “Simulation of Gelatin Nanofiber Scaffold Enhances Cell Adhesion and Proliferation.”, 
Journal bioactive and compatible polymers.(SCI IF=2.610, Ranking 14/79<25%) (accepted) 
3. Shyh Ming Kuo, Shwu Jen Chang, Cheng-Wen Lan, Yueh-Sheng Chen*, Guo-Chung Dong*, 
Chun-Hsu Yao* 2011, “Effects of Collagen Nano-spheres on Cell Cultures”,  2011/4/11 
 Current Nanoscience. (revised)  
4. Guo-Chung Dong* 2011, “screening EGFR modulator from TCM”, Journal of Medicinal Chemistry,  
(preparing) 
5. Guo-Chung Dong*, “Development of Traditional Chinese Medicine-containing Medical Device”, 2nd 
Japan-Taiwan workshop on Advanced Materials and Devices for Further Medical Engineering 
Applications, 2010 Nov. 22~26, Taipei, Taiwan. (invited presentation) 
6. Guo-Chung Dong* and Chun-Hsu Yao, “Kinetic Studies on The Interaction Between EGFR and EGF 
and Its Traditional Chinese Medicine-modulation by Surface Plasmon Resonance”, 3rd International 
Conference on Biomedical Engineering and Informatics, 2010 Oct. 16~18, Yantai, China. (poster 
presentation) 
7. Guo-Chung Dong1*, Chi-Han Li1, Hui-Wen Chang1 and Chun-Hsu Yao, “Screening of Traditional 
Chinese Medicine for Anti-cancer by EGFR protein chips”, 2nd International Conference on Cellular 
and Molecular Bioengineering, 2010 Aug. 1~5, Singapore. (oral presentation) 
 
 10
 
國科會補助專題研究計畫項下出席國際學術會議心得報告 
                                     日期：   年   月   日 
一、參加會議經過 
二、與會心得 
三、考察參觀活動(無是項活動者略) 
四、建議 
五、攜回資料名稱及內容 
六、其他 
計畫編號 NSC 99－2218－E －400 －002－ 
計畫名稱 利用 SPR 研究 EGFR 之固定化及其應用於中藥篩選 
出國人員
姓名 董國忠 
服務機構
及職稱 
財團法人國家衛生研究院醫學工
程研究組助研究員 
會議時間 
99 年 10 月 16 日
至 99 年 10 月 18
日 
會議地點 中國煙台 
會議名稱 
(中文)第三屆國際生物醫學工程及資訊會議 
(英文)2010 3rd International Conference on Biomedical Engineering and Informatics 
發表論文
題目 
(中文)以 SPR 動力學研究 EGFR 及 EGF 之交互作用以及其中藥之調控 
(英文) Kinetic Studies on The Interaction Between EGFR and EGF 
and Its Traditional Chinese Medicine-modulation by Surface Plasmon Resonance 
附件四 
 12
  
   
 17 日參與 Rehabilitation engineering and Innovation 以及 biomedical medicine, materials 
and tissue engineering 兩個分組討論，顯示人工輔具的設計與生醫材料的合成還是大多數研究的重
心，但由於與會人士大陸地區居多，大陸於生醫材料發展還處於萌芽期，突破性生醫材料並未見。本
人於此會議雖然未被列入口頭報告，僅以海報呈現，論文主題以小分子調控癌細胞標的蛋白的動力學
研究，希望呈現生醫材料表面處理的未來走向，由於小分子來源自中草藥，引起許多與會大陸人士注
意，本人並積極尋求大陸研究單位提供中草藥原料，亦引起多位教授熱切關注。 
   
 本論文目的在研究小分子調控 EGFR 蛋白的動力學機制。其中，由中草藥中尋得多種小分子具有促
進或抑制 EGFR 與 EGF 的交互作用，本實驗利用 SPR 偵測模式，瞭解小分子調控過程的動力學訊息，藉
此動力學來推斷小分子與 EGFR 的作用機制，以及小分子作用於蛋白質的位置。結果顯示，具抑制效果
的小分子，主要作用在配基結合區上，使結合現象降低。反之，具促進效果的小分子，可能作用在非
配基結合區上，引發 EGFR 構形改變，使配基結合區暴露，增加結合作用，並且形成更多結合力，使分
離作用也因此降低。此研究對需多複合生醫材料提供一個增強蛋白辨識的方法，在特定小分子作用下，
標的奈米粒子可藉此增加選擇性，進而降低作用在正常細胞所引發的副作用，抑制劑將被發展抑制副
作用的產生，提升生醫材料的可用性。 
Kinetic Studies on The Interaction Between EGFR and EGF
and Its Traditional Chinese Medicine-modulation 
by Surface Plasmon Resonance
Guo---- Chung Dong*   *   *   *  Division of Medical Engineering Research, National Health Research Institutes, NHRI, Zhunan, TaiwanChun----Hsu    Yao        Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan
Abstract—
Epidermal growth factor receptor (EGFR) is an important target on cancer therapy. One of the approaches is to modulate EGFR induced ligand-binding affinity change. In order to
understand the correlation between ligand-binding change and EGFR modulation, we try to get some small molecular agents from traditional Chinese medicines (TCMs) to modulate EGFR
activity on the biosensor system. Among 60 of TCMs, we find that some samples exhibit different influence on EGFR modulation. Among these, 051 showed a more inhibitive property due to
decreasing EGF-affinity, -binding to EGFR and existed an anti-EGFR activity to A549 cells. On the other hand, 040 exist opposite function to 051. 040 is a most powerful enhancer that can
increase the affinity and quantity of EGF binding to EGFR and a pro-EGFR activity on cell culture system. In our study, we can successfully regulate the EGFR-mediated cell proliferation and
anti-apoptosis by modulating the affinity of EGF-EGFR interaction. This way will be a useful method to apply on the therapy of human diseases.
Keywords-
epidermal growth factor receptor; traditional chinese medicine; surface plasmon resonance
INTRODUCTIONI T TII T TII T TIThe epidermal growth factor receptor (EGFR) is a member of the erbB family of receptor tyrosine kinases,
which consist of an extracellular domain that can bind ligands, a transmembrane domain and an intracellular
tyrosine kinase domain. Numerous studies reported over-expression of EGFR in various human cancers. EGFR
protein tyrosine kinase is activated when the extracellular binding domain bind to EGF and then initiate a
downstream cascade of events culminating in cellular responses such as cell proliferation or anti-apoptosis
Ligand binding has been suggested to play an important role in EGFR signal transduction. Some drugs that
block binding of ligands to EGFR have been approved by the FDA. But the problems of side effects cannot solve
completely In previous study, we already set up a screen platform based on protein-protein interaction. So, we
want to use the screen system to get some small molecular agents that modulate binding of l igands to EGFR
from TCMs.
RESULTSLTLTLTTo investigate the modulating effect of TCMs on EGF-EGFR binding, the SPR-based protein interaction
system was performed. The difference of EGF-EGFR binding affinity with or without TCM treatment has been
studied on this system. Among 60 of TCMs, 040 and 100 can increase the KA value of EGF-EGFR binding,
especially 040 was a most effective enhancer. On the other hand, 051 and 002 can increase the KD value of
EGF-EGFR binding, especially 051 was a most remarkable inhibitor (Fig 4). In following studies, 040 and 051,
two significant modulators and 035, a negative control were chosen the test samples.
In vitro interaction analyses showed 040 can enhance the EGF-EGFR binding affinity by increasing the
quantity and association rate (ka) and decrease the dissociation rate (kd) of EGF bind to EGFR; In contrast to
040, 051 existed the opposite effect from 040 (Fig 5 and Table 1). 035 did not have significant effect on this
experiment.
We also check 3 of TCMs in A549 cell culture model. In 10ug/ml treatment, 040 can increase the cell numbers
of A549 and 051 existed the opposite effect from 040 (Fig 6). So, 040 has pro-EGFR but 051 has a anti-EGFR
effect on A549 cell.
CONCLUSIONONCLUSIONONCLUSIONONCLUSIONIn our data, the binding affinity and bioactivity seem to exist a positive correlation. And then we can
successful ly regulate the EGFR-mediated cell prol iferation and anti-apoptosis by modulating the affinity of
EGF-EGFR interaction. This observation could be applied on the modulation of other disease-associated
receptors and be helpful on the therapy of human diseases.
MATERIALST I LT I LT I L AND METHODSTTT1111 .... Recombinanteco binanteco binanteco binant proteinsproteinsproteinsproteins andandandand antibodiesantibodiesantibodiesantibodiesHuman EGF was purchased from PeproTech Inc. and human EGFR was purchased from R&D systems Inc.
Recombinant human EGF was a 6.2 KDa globular protein containing 53 amino acid residues including 3
intramolecular disulfide-bonds. Recombinant human EGFR was a disulfide-linked homodimeric protein
consisting of the extracellular domain (645 aa) of human EGFR fused to the Fc region of human IgG via a
linker peptide. Anti-human EGFR antibody and Anti-phosphotyrosine antibody was obtained from GeneTex Inc.
2222 .... Chemicalshe icalshe icalshe icals andandandand ReagentseagentseagentseagentsCM5 sensor chip, HBS-EP buffer (10 mM HEPES, 0.15 M NaCl, 3.4 mM EDTA, 0.05% surfactant P20, pH 7.4),
and amine-coupling kit containing N-hydroxysuccinimide (NHS), N-ethyl-N-(3-diethylaminopropyl) carbodiimide
(EDS), and ethanolamine hydrochloride were obtained from Biocore AB (Uppsala, Sweden). Phosphate
buffered saline (PBS), Sodium anhydrate was obtained from Sigma Aldrich (Mu‥ nchen, Germany).
3333 .... TCMTTT extractionextractionextractionextractionTwenty grams of TCM was extracted with methanol (200 mL) by stirring at room temperature for 20 min. The
mathanol extracts were collected and fi ltered through filter paper (No.1, code no. PW300-1125, pore size=10
µm, TOYO Inc.). Extraction was repeated three times. All fi ltrates were collected and dried under reduced
pressure. Next, 10 mL PBS was added to dissolve the extract. Afterward, the solution was centrifuged at 8000
rpm for 60 min. The supernatant was collected and then completely dried under reduced pressure.
4444 .... Biacoreiacoreiacoreiacore operationoperationoperationoperation ：The BIACORE 3000 was used as a fully automated optical biosensor system based on surface plasmon
resonance. All investigations were performed with dextran-hydrogel-covered sensor chips, CM5 chips, at 25℃.
EGFR was coupled on the flow cells with the amine coupling kit and the binding of TCMs or EGF was recorded
in real time, leading to a sensorgram in which the relative signal change (RU).
5555 .... Cel lel lel lel l viabili tyviabili tyviabili tyviabili ty assayassayassayassay ：The MTT Cell Proliferation Assay is a colorimetric assay system which measures the reduction of a tetrazol ium
component (MTT) into an insoluble formazan product by the mitochondria of viable cells. After incubation of the
cells with the MTT reagent for approximately 2 to 4 hours, a detergent solution is added to lyse the cells and
solubilize the colored crystals. The samples are read using an ELISA plate reader at a wavelength of 570 nm.
The amount of color produced is directly proportional to the number of viable cells.
-0.5
0.0
0.5
1.0
1.5
2.0
2.5
3.0
0.0 0.5 1.0 1. 5 2.0 2. 5 3.0 3.5
Log KA (1/uM)
Lo
g 
KD
 
(n
M
)
040
051
EGF
035
-200
0
200
400
600
800
1000
0 50 100 150 200 250 300 350 400
T ime (s)
Re
sp
o
n
ce
 
(R
U
)
EGF
51 treatment
41 treatment
0
20
40
60
80
100
120
140
160
180
Bla
nk
EGF
25n
g
051
 1 0
ug+
EG
F 25
ng
040
  10
ug+
E G
F 25
ng
035
  10
ug+
EG
F 25
ng
051
  10
0ug
+EG
F 2
5ng
040
  10
0ug
+EG
F  2
5ng
035
  10
0ug
+EG
F 2
5ng
ce
ll 
via
bil
ity
 (%
)
Normal cell Cancer cell
Over-expression
Survival
(anti-apoptosis)
Proliferation/
maturation
Angiogenesis
MetastasisChemotherapy /
radiotherapy
resistance
Normal cell
Low-affinity
95~98%
slow
Cancer cell
High-affinity
fast
For kon
For koff
SPR
EGF
Normal cell Cancer cell
KD or ka, kd
Acknowledgements
The authors would like to thank the National Science Council of the Republic of China for financially supporting this
research under Contract No. NSC99-2218-E-400-002.
REFERENCES
1.  Journal of Medicinal Chemistry , 49, 6, 1845-1854. 2006 (Impact Factor=4.898, Ranking 3/41(=7.3%)) 
2.  Biomaterials, 28, 27, 3996-4005. 2007 (Impact Factor=6.646, Ranking 2/52(<5%)
3.  Pharmaceuticals, 14-15.2007
4.  Pharmaceutical Research, 26, 2, 375-381.2008 (Impact Factor=4.024, Ranking 20/127(=15.75%))  
 18 日參與 Biomedical instrumentation, Devices, and Sensors 分組討論。其中，由中國科學
 1
 
國科會補助專題研究計畫項下出席國際學術會議心得報告 
                                     日期：   年   月   日 
一、參加會議經過 
二、與會心得 
三、考察參觀活動(無是項活動者略) 
四、建議 
五、攜回資料名稱及內容 
六、其他 
計畫編號 NSC 99－2218－E －400 －002－ 
計畫名稱 利用 SPR 研究 EGFR 之固定化及其應用於中藥篩選 
出國人員
姓名 董國忠 
服務機構
及職稱 
財團法人國家衛生研究院醫學工
程研究組助研究員 
會議時間 
99 年 10 月 16 日
至 99 年 10 月 18
日 
會議地點 中國煙台 
會議名稱 
(中文)第三屆國際生物醫學工程及資訊會議 
(英文)2010 3rd International Conference on Biomedical Engineering and Informatics 
發表論文
題目 
(中文)以 SPR 動力學研究 EGFR 及 EGF 之交互作用以及其中藥之調控 
(英文) Kinetic Studies on The Interaction Between EGFR and EGF 
and Its Traditional Chinese Medicine-modulation by Surface Plasmon Resonance 
附件四 
 3
  
   
 17 日參與 Rehabilitation engineering and Innovation 以及 biomedical medicine, materials 
and tissue engineering 兩個分組討論，顯示人工輔具的設計與生醫材料的合成還是大多數研究的重
心，但由於與會人士大陸地區居多，大陸於生醫材料發展還處於萌芽期，突破性生醫材料並未見。本
人於此會議雖然未被列入口頭報告，僅以海報呈現，論文主題以小分子調控癌細胞標的蛋白的動力學
研究，希望呈現生醫材料表面處理的未來走向，由於小分子來源自中草藥，引起許多與會大陸人士注
意，本人並積極尋求大陸研究單位提供中草藥原料，亦引起多位教授熱切關注。 
   
 本論文目的在研究小分子調控 EGFR 蛋白的動力學機制。其中，由中草藥中尋得多種小分子具有促
進或抑制 EGFR 與 EGF 的交互作用，本實驗利用 SPR 偵測模式，瞭解小分子調控過程的動力學訊息，藉
此動力學來推斷小分子與 EGFR 的作用機制，以及小分子作用於蛋白質的位置。結果顯示，具抑制效果
的小分子，主要作用在配基結合區上，使結合現象降低。反之，具促進效果的小分子，可能作用在非
配基結合區上，引發 EGFR 構形改變，使配基結合區暴露，增加結合作用，並且形成更多結合力，使分
離作用也因此降低。此研究對需多複合生醫材料提供一個增強蛋白辨識的方法，在特定小分子作用下，
標的奈米粒子可藉此增加選擇性，進而降低作用在正常細胞所引發的副作用，抑制劑將被發展抑制副
作用的產生，提升生醫材料的可用性。 
Kinetic Studies on The Interaction Between EGFR and EGF
and Its Traditional Chinese Medicine-modulation 
by Surface Plasmon Resonance
Guo---- Chung Dong*   *   *   *  Division of Medical Engineering Research, National Health Research Institutes, NHRI, Zhunan, TaiwanChun----Hsu    Yao        Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan
Abstract—
Epidermal growth factor receptor (EGFR) is an important target on cancer therapy. One of the approaches is to modulate EGFR induced ligand-binding affinity change. In order to
understand the correlation between ligand-binding change and EGFR modulation, we try to get some small molecular agents from traditional Chinese medicines (TCMs) to modulate EGFR
activity on the biosensor system. Among 60 of TCMs, we find that some samples exhibit different influence on EGFR modulation. Among these, 051 showed a more inhibitive property due to
decreasing EGF-affinity, -binding to EGFR and existed an anti-EGFR activity to A549 cells. On the other hand, 040 exist opposite function to 051. 040 is a most powerful enhancer that can
increase the affinity and quantity of EGF binding to EGFR and a pro-EGFR activity on cell culture system. In our study, we can successfully regulate the EGFR-mediated cell proliferation and
anti-apoptosis by modulating the affinity of EGF-EGFR interaction. This way will be a useful method to apply on the therapy of human diseases.
Keywords-
epidermal growth factor receptor; traditional chinese medicine; surface plasmon resonance
INTRODUCTIONI T TII T TII T TIThe epidermal growth factor receptor (EGFR) is a member of the erbB family of receptor tyrosine kinases,
which consist of an extracellular domain that can bind ligands, a transmembrane domain and an intracellular
tyrosine kinase domain. Numerous studies reported over-expression of EGFR in various human cancers. EGFR
protein tyrosine kinase is activated when the extracellular binding domain bind to EGF and then initiate a
downstream cascade of events culminating in cellular responses such as cell proliferation or anti-apoptosis
Ligand binding has been suggested to play an important role in EGFR signal transduction. Some drugs that
block binding of ligands to EGFR have been approved by the FDA. But the problems of side effects cannot solve
completely In previous study, we already set up a screen platform based on protein-protein interaction. So, we
want to use the screen system to get some small molecular agents that modulate binding of l igands to EGFR
from TCMs.
RESULTSLTLTLTTo investigate the modulating effect of TCMs on EGF-EGFR binding, the SPR-based protein interaction
system was performed. The difference of EGF-EGFR binding affinity with or without TCM treatment has been
studied on this system. Among 60 of TCMs, 040 and 100 can increase the KA value of EGF-EGFR binding,
especially 040 was a most effective enhancer. On the other hand, 051 and 002 can increase the KD value of
EGF-EGFR binding, especially 051 was a most remarkable inhibitor (Fig 4). In following studies, 040 and 051,
two significant modulators and 035, a negative control were chosen the test samples.
In vitro interaction analyses showed 040 can enhance the EGF-EGFR binding affinity by increasing the
quantity and association rate (ka) and decrease the dissociation rate (kd) of EGF bind to EGFR; In contrast to
040, 051 existed the opposite effect from 040 (Fig 5 and Table 1). 035 did not have significant effect on this
experiment.
We also check 3 of TCMs in A549 cell culture model. In 10ug/ml treatment, 040 can increase the cell numbers
of A549 and 051 existed the opposite effect from 040 (Fig 6). So, 040 has pro-EGFR but 051 has a anti-EGFR
effect on A549 cell.
CONCLUSIONONCLUSIONONCLUSIONONCLUSIONIn our data, the binding affinity and bioactivity seem to exist a positive correlation. And then we can
successful ly regulate the EGFR-mediated cell prol iferation and anti-apoptosis by modulating the affinity of
EGF-EGFR interaction. This observation could be applied on the modulation of other disease-associated
receptors and be helpful on the therapy of human diseases.
MATERIALST I LT I LT I L AND METHODSTTT1111 .... Recombinanteco binanteco binanteco binant proteinsproteinsproteinsproteins andandandand antibodiesantibodiesantibodiesantibodiesHuman EGF was purchased from PeproTech Inc. and human EGFR was purchased from R&D systems Inc.
Recombinant human EGF was a 6.2 KDa globular protein containing 53 amino acid residues including 3
intramolecular disulfide-bonds. Recombinant human EGFR was a disulfide-linked homodimeric protein
consisting of the extracellular domain (645 aa) of human EGFR fused to the Fc region of human IgG via a
linker peptide. Anti-human EGFR antibody and Anti-phosphotyrosine antibody was obtained from GeneTex Inc.
2222 .... Chemicalshe icalshe icalshe icals andandandand ReagentseagentseagentseagentsCM5 sensor chip, HBS-EP buffer (10 mM HEPES, 0.15 M NaCl, 3.4 mM EDTA, 0.05% surfactant P20, pH 7.4),
and amine-coupling kit containing N-hydroxysuccinimide (NHS), N-ethyl-N-(3-diethylaminopropyl) carbodiimide
(EDS), and ethanolamine hydrochloride were obtained from Biocore AB (Uppsala, Sweden). Phosphate
buffered saline (PBS), Sodium anhydrate was obtained from Sigma Aldrich (Mu‥ nchen, Germany).
3333 .... TCMTTT extractionextractionextractionextractionTwenty grams of TCM was extracted with methanol (200 mL) by stirring at room temperature for 20 min. The
mathanol extracts were collected and fi ltered through filter paper (No.1, code no. PW300-1125, pore size=10
µm, TOYO Inc.). Extraction was repeated three times. All fi ltrates were collected and dried under reduced
pressure. Next, 10 mL PBS was added to dissolve the extract. Afterward, the solution was centrifuged at 8000
rpm for 60 min. The supernatant was collected and then completely dried under reduced pressure.
4444 .... Biacoreiacoreiacoreiacore operationoperationoperationoperation ：The BIACORE 3000 was used as a fully automated optical biosensor system based on surface plasmon
resonance. All investigations were performed with dextran-hydrogel-covered sensor chips, CM5 chips, at 25℃.
EGFR was coupled on the flow cells with the amine coupling kit and the binding of TCMs or EGF was recorded
in real time, leading to a sensorgram in which the relative signal change (RU).
5555 .... Cel lel lel lel l viabili tyviabili tyviabili tyviabili ty assayassayassayassay ：The MTT Cell Proliferation Assay is a colorimetric assay system which measures the reduction of a tetrazol ium
component (MTT) into an insoluble formazan product by the mitochondria of viable cells. After incubation of the
cells with the MTT reagent for approximately 2 to 4 hours, a detergent solution is added to lyse the cells and
solubilize the colored crystals. The samples are read using an ELISA plate reader at a wavelength of 570 nm.
The amount of color produced is directly proportional to the number of viable cells.
-0.5
0.0
0.5
1.0
1.5
2.0
2.5
3.0
0.0 0.5 1.0 1. 5 2.0 2. 5 3.0 3.5
Log KA (1/uM)
Lo
g 
KD
 
(n
M
)
040
051
EGF
035
-200
0
200
400
600
800
1000
0 50 100 150 200 250 300 350 400
T ime (s)
Re
sp
o
n
ce
 
(R
U
)
EGF
51 treatment
41 treatment
0
20
40
60
80
100
120
140
160
180
Bla
nk
EGF
25n
g
051
 1 0
ug+
EG
F 25
ng
040
  10
ug+
E G
F 25
ng
035
  10
ug+
EG
F 25
ng
051
  10
0ug
+EG
F 2
5ng
040
  10
0ug
+EG
F  2
5ng
035
  10
0ug
+EG
F 2
5ng
ce
ll 
via
bil
ity
 (%
)
Normal cell Cancer cell
Over-expression
Survival
(anti-apoptosis)
Proliferation/
maturation
Angiogenesis
MetastasisChemotherapy /
radiotherapy
resistance
Normal cell
Low-affinity
95~98%
slow
Cancer cell
High-affinity
fast
For kon
For koff
SPR
EGF
Normal cell Cancer cell
KD or ka, kd
Acknowledgements
The authors would like to thank the National Science Council of the Republic of China for financially supporting this
research under Contract No. NSC99-2218-E-400-002.
REFERENCES
1.  Journal of Medicinal Chemistry , 49, 6, 1845-1854. 2006 (Impact Factor=4.898, Ranking 3/41(=7.3%)) 
2.  Biomaterials, 28, 27, 3996-4005. 2007 (Impact Factor=6.646, Ranking 2/52(<5%)
3.  Pharmaceuticals, 14-15.2007
4.  Pharmaceutical Research, 26, 2, 375-381.2008 (Impact Factor=4.024, Ranking 20/127(=15.75%))  
 18 日參與 Biomedical instrumentation, Devices, and Sensors 分組討論。其中，由中國科學
無研發成果推廣資料 
其他成果 
(無法以量化表達之成
果如辦理學術活動、獲
得獎項、重要國際合
作、研究成果國際影響
力及其他協助產業技
術發展之具體效益事
項等，請以文字敘述填
列。) 
無 
 成果項目 量化 名稱或內容性質簡述 
測驗工具(含質性與量性) 0  
課程/模組 0  
電腦及網路系統或工具 0  
教材 0  
舉辦之活動/競賽 0  
研討會/工作坊 0  
電子報、網站 0  
科 
教 
處 
計 
畫 
加 
填 
項 
目 計畫成果推廣之參與（閱聽）人數 0  
 
